secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116529
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Irish High Court confirms Mallinckrodt scheme, paving exit from Chapter 11
--------------------------------------------------------------------------

- Scheme confirmed by Irish High Court on Nov 10, effective on Plan effective date expected Nov 14, 2023.
- Existing ordinary shares cancelled without any payment or distribution to shareholders.
- New common equity issued to creditors in accordance with Plan; not expected to be listed on any exchange.
- Company expects to emerge from Chapter 11 in coming days after satisfaction of remaining conditions.
- Shares trade over-the-counter under MNKTQ; delisted from NYSE American in September 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465923116529/0001104659-23-116529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465923116529/tm2330452d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer